Technical Analysis for XOMA - XOMA Corporation

Grade Last Price % Change Price Change
grade B 17.75 3.50% 0.60
XOMA closed up 3.5 percent on Wednesday, August 21, 2019, on 1.36 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical XOMA trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Fell Below 20 DMA Bearish 3.50%
Fell Below 50 DMA Bearish 3.50%
NR7 Range Contraction 3.50%
Inside Day Range Contraction 3.50%
Crossed Above 20 DMA Bullish 0.17%

Older signals for XOMA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
Medicine Health Immunology Diabetes Solid Tumors Antibodies Immune System Monoclonal Antibodies Non Small Cell Lung Cancer Antibody Multiple Myeloma Hypertension Cardiovascular Diseases Metabolic Disorders Uveitis Inflammatory Development Technologies Non Infectious Uveitis
Is XOMA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.29
52 Week Low 11.02
Average Volume 84,191
200-Day Moving Average 14.844
50-Day Moving Average 17.178
20-Day Moving Average 17.3785
10-Day Moving Average 16.94
Average True Range 1.1289
ADX 20.48
+DI 19.1175
-DI 20.9613
Chandelier Exit (Long, 3 ATRs ) 16.9033
Chandelier Exit (Short, 3 ATRs ) 18.6867
Upper Bollinger Band 19.2462
Lower Bollinger Band 15.5108
Percent B (%b) 0.6
BandWidth 21.494375
MACD Line -0.0808
MACD Signal Line -0.1155
MACD Histogram 0.0347
Fundamentals Value
Market Cap 134.86 Million
Num Shares 7.6 Million
EPS -6.93
Price-to-Earnings (P/E) Ratio -2.56
Price-to-Sales 13.67
Price-to-Book 0.00
PEG Ratio -0.40
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.33
Resistance 3 (R3) 19.30 18.74 19.06
Resistance 2 (R2) 18.74 18.34 18.76 18.97
Resistance 1 (R1) 18.25 18.09 18.50 18.28 18.89
Pivot Point 17.69 17.69 17.82 17.71 17.69
Support 1 (S1) 17.20 17.29 17.45 17.23 16.61
Support 2 (S2) 16.64 17.04 16.66 16.53
Support 3 (S3) 16.15 16.64 16.44
Support 4 (S4) 16.18